{"product_id":"tcrt-vrio-analysis","title":"Alaunos Therapeutics, Inc. (TCRT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets behind Alaunos Therapeutics, Inc. (TCRT)'s market standing with this distilled VRIO Analysis. We cut straight to the core, assessing whether their assets are truly Valuable, Rare, Inimitable, and Organized to forge a sustainable competitive advantage. Dive in now to see the precise strengths and weaknesses that define their success story.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlaunos Therapeutics, Inc. (TCRT) - VRIO Analysis: 1. hunTR® TCR Discovery Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re a leader looking at Alaunos Therapeutics, Inc. (TCRT) after they made the tough call to stop their clinical trial and pivot hard toward their discovery engine. The core question now is whether that engine, the hunTR® platform, can actually deliver a sustained competitive edge, especially given the tight cash situation we saw in the Q3 2025 filings.\u003c\/p\u003e\n\n\u003cp\u003eThe platform itself is designed to create wholly owned, proprietary T-cell receptors (TCRs) that target driver mutations like KRAS and TP53. This is the engine for any future pipeline development, which is critical since the previous TCR-T Library trial is winding down. Honestly, the company’s survival hinges on this technology proving out its value quickly.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on their current footing: As of September 30, 2025, Alaunos reported cash and equivalents of only about \u003cstrong\u003e$1.93 million\u003c\/strong\u003e. Management noted this cash only funds operations into Q1 2026, which puts immense pressure on the hunTR® platform to generate validation data or secure a deal fast. What this estimate hides is the burn rate required to keep the platform running while exploring strategic alternatives.\u003c\/p\u003e\n\n\u003cp\u003eThe strategic realignment shows the organization is focused, but the clock is ticking loud. If onboarding takes 14+ days to show positive pre-clinical results, the risk of a liquidity crunch rises defintely.\u003c\/p\u003e\n\n\u003cp\u003eHere is the breakdown of the hunTR® TCR Discovery Platform using the VRIO framework:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Dimension\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2025 Context \u0026amp; Data Point\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue (V)\u003c\/td\u003e\n    \u003ctd\u003eCreates wholly owned, proprietary TCRs\u003c\/td\u003e\n    \u003ctd\u003eIt is the engine for future pipeline development after halting the TCR-T Phase 1\/2 Library trial.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity (R)\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eProprietary, rapid, cost-effective solutions for TCR discovery are not common among smaller biotechs.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability (I)\u003c\/td\u003e\n    \u003ctd\u003eMedium\u003c\/td\u003e\n    \u003ctd\u003eThe underlying science is known, but the specific, optimized library and workflow are hard to replicate quickly.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization (O)\u003c\/td\u003e\n    \u003ctd\u003eModerate\u003c\/td\u003e\n    \u003ctd\u003eThe company is clearly organized to exploit this by reprioritizing focus onto it after discontinuing the trial.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eIt’s their main asset now; sustained advantage depends on successful validation of new TCRs before cash runs out (\u003cstrong\u003e$1.93 million\u003c\/strong\u003e cash as of 9\/30\/2025).\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe current state of the platform suggests it is a valuable and rare asset, but the moderate imitability and the company’s immediate financial constraints prevent it from being a sustained advantage right now. They need to move from discovery to demonstrable, de-risked assets.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003eValue Drivers:\u003c\/strong\u003e Proprietary TCRs targeting driver mutations (KRAS, TP53, EGFR).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFinancial Pressure:\u003c\/strong\u003e Net loss for Q3 2025 was \u003cstrong\u003e$1.15 million\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKey Action Required:\u003c\/strong\u003e Rapidly validate new TCR candidates to attract strategic partners or funding.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlaunos Therapeutics, Inc. (TCRT) - VRIO Analysis: 2. Sleeping Beauty Non-Viral Gene Transfer Platform\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below focuses solely on quantifiable, real-life data points relevant to the VRIO framework for the Sleeping Beauty Non-Viral Gene Transfer Platform.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for the genetic modification of T cells without using potentially risky viral vectors, which is a key differentiator in cell therapy manufacturing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; non-viral platforms for TCR-T therapy are less common than established lentiviral methods.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; while the concept exists, the specific, optimized, and validated non-viral system is proprietary.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this platform is integral to their in-house manufacturing process, showing organizational alignment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; if it proves safer or more scalable than viral alternatives, it offers a long-term edge.\u003c\/p\u003e\n\n\u003cp\u003eThe platform's operational and clinical performance metrics include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProof-of-concept demonstrated with all manufactured products achieving \u003cstrong\u003e\u0026gt;90%\u003c\/strong\u003e TCR positivity.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses were \u003cstrong\u003e$3.7 million\u003c\/strong\u003e for the third quarter of 2023, a decrease of approximately \u003cstrong\u003e54%\u003c\/strong\u003e from \u003cstrong\u003e$7.9 million\u003c\/strong\u003e in the third quarter of 2022.\u003c\/li\u003e\n\u003cli\u003eThe non-viral Sleeping Beauty gene transfer platform patent is noted to expire in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUnder a \u003cstrong\u003e2019 R\u0026amp;D Agreement\u003c\/strong\u003e, the company agreed to reimburse MD Anderson up to a total of \u003cstrong\u003e$20 million\u003c\/strong\u003e for development costs, beginning January 1, \u003cstrong\u003e2021\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2023, cash balances were approximately \u003cstrong\u003e$11.9 million\u003c\/strong\u003e, with cost-savings measures expected to extend cash runway into the \u003cstrong\u003esecond quarter of 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eEarly clinical data from the TCR-T Library Phase 1\/2 trial, as of the third quarter of 2023, involved \u003cstrong\u003eeight\u003c\/strong\u003e evaluable patients:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Evaluated Patients\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisease Control Rate (DCR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e87%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Achieving Stable Disease (Best Overall Response)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients with Objective Partial Response (OPR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNSCLC Patient OPR with Progression-Free Survival\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported CRS Event Grades\u003c\/td\u003e\n\u003ctd\u003eGrades \u003cstrong\u003e1-3\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe patient breakdown for the \u003cstrong\u003eeight\u003c\/strong\u003e treated patients was:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePancreatic cancer: \u003cstrong\u003e3\u003c\/strong\u003e patients\u003c\/li\u003e\n\u003cli\u003eColorectal cancer: \u003cstrong\u003e4\u003c\/strong\u003e patients\u003c\/li\u003e\n\u003cli\u003eNon-small cell lung cancer (NSCLC): \u003cstrong\u003e1\u003c\/strong\u003e patient\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlaunos Therapeutics, Inc. (TCRT) - VRIO Analysis: 3. Proprietary TCR Library Targeting Hotspot Mutations\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Targets shared tumor-specific hotspot mutations in KRAS, TP53, and EGFR across six solid tumor indications: non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Initial library contained ten TCRs. In Q4 2022, two new TCRs were added, doubling the potential addressable market. Expansion planned to 15 TCRs by the end of 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Non-viral Sleeping Beauty platform produced cell products with \u0026gt;90% TCR positivity.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Decision to halt the sole clinical study announced August 2023. Cost-saving measures expected to extend cash runway into Q2 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Objective Clinical Response observed in one patient with NSCLC.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patients Evaluated (as of Q3 2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisease Control Rate (DCR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e87%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBest Objective Response\u003c\/td\u003e\n\u003ctd\u003ePartial Response (1 patient)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBest Overall Response (Non-PR)\u003c\/td\u003e\n\u003ctd\u003eStable Disease (6 patients)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTCR Positivity in Manufactured Cells\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Levels Tested (Initial)\u003c\/td\u003e\n\u003ctd\u003eThree cohorts: 5x10\u003csup\u003e9\u003c\/sup\u003e, 4x10\u003csup\u003e10\u003c\/sup\u003e, 1x10\u003csup\u003e11\u003c\/sup\u003e TCR-T cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial and Operational Metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash balance as of June 2023-end: \u003cstrong\u003e$18.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Income (for fiscal year ending 2024-12-31): \u003cstrong\u003e$-4.68M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRevenue (for fiscal year ending 2024-12-31): \u003cstrong\u003e$0.01M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and Development Expenses (Q4 2022): \u003cstrong\u003e$5.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative Expenses (Q4 2022): \u003cstrong\u003e$2.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eShares Outstanding: \u003cstrong\u003e2.23 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTCR-T Library Phase 1\/2 Trial Identifier: NCT\u003cstrong\u003e05194735\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlaunos Therapeutics, Inc. (TCRT) - VRIO Analysis: 4. State-of-the-Art cGMP In-House Manufacturing Facility\n\u003c\/h2\u003e\n\u003cp\u003eThe in-house cGMP manufacturing facility supports the production of Alaunos' Phase 1 TCR-T cell products near the Texas Medical Center in Houston, Texas.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Control over the production of their TCR-T cell products, enabling rapid process improvements and positioning for future commercial scale. The ability to rapidly move improvements from the lab into the cGMP suite enables manufacturing processes to remain at the cutting-edge during early clinical development.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe facility is staffed by Alaunos personnel and is fully operational for manufacturing and release of clinical product.\u003c\/li\u003e\n\u003cli\u003eThe proprietary nonviral gene transfer platform, Sleeping Beauty, is utilized within the facility to genetically modify the patient's T cells.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many clinical-stage biotechs outsource, so having an operational, in-house facility is a resource advantage. The Company \u003cstrong\u003edoubled its manufacturing capacity in 2022\u003c\/strong\u003e, allowing for the production of \u003cstrong\u003etwo products simultaneously\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe leased space associated with the headquarters, which houses the facility, was reduced from \u003cstrong\u003e18,111 square feet\u003c\/strong\u003e to \u003cstrong\u003e3,228 square feet\u003c\/strong\u003e as of the second quarter of 2022.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; building a cGMP facility requires massive capital expenditure and regulatory hurdles, making it hard to copy. Operation requires knowledgeable individuals with previous experience in cleanroom environments.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the facility is staffed by Alaunos personnel and is fully operational for manufacturing and release.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility Location\u003c\/td\u003e\n\u003ctd\u003eHouston, Texas (near Texas Medical Center)\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Status\u003c\/td\u003e\n\u003ctd\u003eFully operational for manufacturing and release\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity Change\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eDoubled\u003c\/strong\u003e manufacturing capacity\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSimultaneous Production\u003c\/td\u003e\n\u003ctd\u003eAbility to produce \u003cstrong\u003etwo products\u003c\/strong\u003e simultaneously\u003c\/td\u003e\n\u003ctd\u003ePost-2022 Capacity Increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeased Space (Relevant Portion)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3,228 square feet\u003c\/strong\u003e (Reduced from 18,111 sq ft)\u003c\/td\u003e\n\u003ctd\u003eAs of Q2 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Operations Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$56.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this physical asset and the expertise within it are difficult and expensive for a competitor to duplicate. The ability to rapidly integrate process improvements into the cGMP suite supports positioning for commercial scale.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe facility must pass satisfactory completion of an FDA inspection to assure compliance with current Good Manufacturing Practice (cGMP) requirements.\u003c\/li\u003e\n\u003cli\u003eEach manufacturing process must be proven through performance of process validation runs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlaunos Therapeutics, Inc. (TCRT) - VRIO Analysis: 5. Process Development Capability for Commercial Scale\n\u003c\/h2\u003e\n\u003cp\u003eThe commitment to improving workflow and analytical development in parallel with manufacturing reduces future technology transfer risk and cost.\u003c\/p\u003e\n\u003cp\u003eThe internal, state-of-the-art cell manufacturing facility supports the clinic by producing autologous TCR-T cell products.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe commitment to improving workflow and analytical development in parallel with manufacturing reduces future technology transfer risk and cost. This is evidenced by the strategic financial management supporting ongoing operations.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Loss for Q3 2023 was \u003cstrong\u003e$8.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and Development Expenses decreased by approximately \u003cstrong\u003e54%\u003c\/strong\u003e to \u003cstrong\u003e$3.7 million\u003c\/strong\u003e for Q3 2023, compared to \u003cstrong\u003e$7.9 million\u003c\/strong\u003e for Q3 2022.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; many early-stage firms lack this dedicated focus on process optimization alongside discovery. The Sleeping Beauty platform is noted for its cost-effectiveness relative to alternatives.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSleeping Beauty transposition is stated to be manufactured at \u003cstrong\u003e'a fraction of the cost'\u003c\/strong\u003e of other gene transfer technologies (viral, gene editing).\u003c\/li\u003e\n\u003cli\u003eThe Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) is extended through \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e, indicating established external validation of the technology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eMedium; the specific know-how gained from optimizing the Sleeping Beauty platform in their own suite is tacit knowledge. The platform enables rapid generation of stable cell lines in a medium-throughput setting of \u003cstrong\u003ethree to five days\u003c\/strong\u003e in optimized laboratory settings.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eSpecific Metric\u003c\/th\u003e\n\u003cth\u003eReported Value\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Position\u003c\/td\u003e\n\u003ctd\u003eCash, Cash Equivalents and Restricted Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Efficiency\u003c\/td\u003e\n\u003ctd\u003eWorkforce Reduction\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e60%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAnnounced August 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Efficacy (DCR)\u003c\/td\u003e\n\u003ctd\u003eDisease Control Rate (TCR-T Library Trial)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e87%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEight evaluable patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology Comparison\u003c\/td\u003e\n\u003ctd\u003eSB Generation Time (Lab Setting)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eThree to five days\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor stable transgenic cell lines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; this capability is explicitly mentioned as a commitment driving their manufacturing strategy. Strategic decisions reflect an organization structured to manage development and scale.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCost-saving measures were expected to extend cash runway into the \u003cstrong\u003esecond quarter of 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company is reprioritizing focus onto its hunTR discovery platform following the discontinuation of its sole clinical-stage asset.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; expertise improves over time, but it’s not a unique barrier to entry on its own. The company's employees are described as the \u003cstrong\u003e'world's leaders in TCR transposition'\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlaunos Therapeutics, Inc. (TCRT) - VRIO Analysis: 6. Strategic Focus on Solid Tumor Neoantigens\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Targets the largest, most underserved segment of the cancer market, offering a potentially massive addressable patient population.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTCR-T Library Phase 1\/2 trial achieved an 87% disease control rate in eight evaluable patients with metastatic, refractory solid tumors as of Q3 2023.\u003c\/li\u003e\n\u003cli\u003eTotal overall response rate was 13% in the same cohort.\u003c\/li\u003e\n\u003cli\u003eOne patient with non-small cell lung cancer (NSCLC) achieved an objective partial response with six months progression-free survival.\u003c\/li\u003e\n\u003cli\u003eAddition of two new TCRs in early 2023 was expected to double the addressable market for TCR-T therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many companies target solid tumors, but Alaunos Therapeutics focuses specifically on neoantigens arising from genomic mutations.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe hunTR® discovery engine is used to identify new TCRs against shared hotspot mutations like KRAS and TP53.\u003c\/li\u003e\n\u003cli\u003eEarly manufacturing demonstrated proof-of-concept with all products achieving \u0026gt;90% TCR positivity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the strategic direction is public, and competitors are also pivoting toward solid tumors.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company announced a strategic reprioritization in August 2023 to focus on the hunTR® platform.\u003c\/li\u003e\n\u003cli\u003eCost-savings measures, including a workforce reduction of approximately 60%, were implemented to extend cash runway into Q2 2024.\u003c\/li\u003e\n\u003cli\u003eResearch and Development Expenses decreased by approximately 54% from $7.9 million (Q3 2022) to $3.7 million (Q3 2023).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this focus dictated the design of the hunTR® library and the now-discontinued clinical trial.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe TCR-T Library Phase 1\/2 trial was an open-label, dose-escalation study conducted at MD Anderson Cancer Center.\u003c\/li\u003e\n\u003cli\u003eThe trial reported no dose-limiting toxicities (DLTs) or ICANS.\u003c\/li\u003e\n\u003cli\u003eAs of December 8, 2025, the Market Capitalization was $9.11M with 2.23 million shares outstanding.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; this is a necessary strategic alignment in the current market, not a unique advantage.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Status\u003c\/td\u003e\n\u003ctd\u003eContext\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisease Control Rate (DCR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e87%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTCR-T Library Phase 1\/2 Trial (8 evaluable patients)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTCR-T Library Phase 1\/2 Trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTCR Positivity in Product\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eManufactured TCR-T cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e52-Week Stock Price Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.31\u003c\/strong\u003e to \u003cstrong\u003e$6.20\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of December 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlaunos Therapeutics, Inc. (TCRT) - VRIO Analysis: 7. Access to Capital via Recent Financing\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe ability to secure a \\$2.0 Million Registered Direct Offering in June 2025 shows continued investor confidence despite clinical setbacks. This was followed by an equity purchase agreement on May 19, 2025, allowing for the sale of up to \\$25 million in common stock over a 24-month period.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate; securing financing in a tough biotech market is rare, especially when pausing a trial. The \\$2.0 Million gross proceeds offering occurred when the company had a Market Capitalization of just \\$7 million.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow; this is a transactional event, not a core, repeatable capability.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh; management successfully executed a financing event to extend the runway.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary; this capital is for survival and R\u0026amp;D pivot, not a sustained market advantage.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRecent Capital Raising Events and Financial Context\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancing Event\u003c\/th\u003e\n\u003cth\u003eDate Announced\/Closed\u003c\/th\u003e\n\u003cth\u003eGross Proceeds (Approximate)\u003c\/th\u003e\n\u003cth\u003eSecurity Type\/Price\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistered Direct Offering\u003c\/td\u003e\n\u003ctd\u003eJune 2025\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\\$2.0 Million\u003c\/strong\u003e or \u003cstrong\u003e\\$2.1 Million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCommon Stock \/ Pre-funded Warrants at \u003cstrong\u003e\\$3.36\u003c\/strong\u003e per share equivalent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity Purchase Agreement\u003c\/td\u003e\n\u003ctd\u003eMay 19, 2025\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e\\$25 Million\u003c\/strong\u003e available over 24 months\u003c\/td\u003e\n\u003ctd\u003eCommon Stock\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeries A-2 Convertible Preferred Stock Subscription\u003c\/td\u003e\n\u003ctd\u003eJune 24, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$850,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeries A-2 Convertible Preferred Stock at \u003cstrong\u003e\\$1,000\u003c\/strong\u003e per stock\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eSelected Financial Metrics Highlighting Need for Capital\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrailing Twelve Months Negative EBITDA: \u003cstrong\u003e-\\$4.16 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Earnings: \u003cstrong\u003e-\\$1.2M\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Revenue: \u003cstrong\u003e\\$2.00 thousand\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Net Loss: \u003cstrong\u003e-\\$1.07 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization (at time of offering): \u003cstrong\u003e\\$7 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet Proceeds from June 2025 Offering: Approximately \u003cstrong\u003e\\$1.9 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlaunos Therapeutics, Inc. (TCRT) - VRIO Analysis: 8. Significant Shareholder Alignment and Influence\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Having an influential shareholder like PMGC Capital, which acquired a \u003cstrong\u003e5.09%\u003c\/strong\u003e stake as of May 2025, can pressure management toward value-maximizing strategic alternatives. This stake represented \u003cstrong\u003e83,500\u003c\/strong\u003e shares based on \u003cstrong\u003e1,639,521\u003c\/strong\u003e outstanding shares as of May 5, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; large, activist-leaning stakes in small-cap biotechs are not uncommon but can force action. The company was actively exploring strategic alternatives, including mergers and acquisitions, at the time of the stake acquisition.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a result of past investment activity, not an internal capability. The ownership structure is dynamic, with Institutional Investors holding \u003cstrong\u003e10.85%\u003c\/strong\u003e and Mutual Funds holding \u003cstrong\u003e3.47%\u003c\/strong\u003e as of November 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the board is currently navigating pressure regarding a term sheet sent on \u003cstrong\u003e5\/25\/2025\u003c\/strong\u003e, showing this influence is active.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; this is an external governance factor that can be volatile. The stock price as of December 2, 2025, was \u003cstrong\u003e3.28 USD\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eVRIO Assessment Summary:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eComponent\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003ePMGC Capital acquired \u003cstrong\u003e5.09%\u003c\/strong\u003e stake, believing the company is undervalued and seeking value creation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eLarge, activist-leaning stakes are not uncommon in small-cap biotechs, but this level of direct engagement is notable.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eResult of external investment activity (\u003cstrong\u003e83,500\u003c\/strong\u003e shares acquired) rather than an internal, inimitable capability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eBoard is actively navigating pressure regarding a financing term sheet proposed on \u003cstrong\u003e5\/25\/2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003ctd\u003eExternal governance factor, subject to volatility based on shareholder sentiment and actions.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional Shareholder Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eShares of common stock outstanding as of March 31, 2025: \u003cstrong\u003e1,601,252\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eInsider holdings as of November 2025: \u003cstrong\u003e0.37%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNumber of analysts covering Alaunos Therapeutics, Inc.: \u003cstrong\u003e17\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlaunos Therapeutics, Inc. (TCRT) - VRIO Analysis: 9. Houston, Texas Biotech Hub Proximity\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Being located near the Texas Medical Center provides access to specialized clinical sites, talent pools, and potential academic collaborations.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Texas Medical Center (TMC) represents one of the world's largest medical complexes.\u003c\/li\u003e\n\u003cli\u003eAlaunos Therapeutics is headquartered in Houston, Texas.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many life science companies are clustered in major hubs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; location is fixed and easily replicated by others moving there.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; it supports operations but doesn't drive the core science itself.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; it’s a supporting factor, not a source of sustained differentiation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: 13-Week Cash Flow Projection Incorporating June 2025 Offering\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe projection incorporates the $2.0 Million gross proceeds from the June 2025 Registered Direct Offering, resulting in net proceeds of approximately $1.9 million. The starting cash balance reflects the Q3 2025 reported figure. Weekly cash outflow is estimated based on the Q3 2025 net change in cash of -$941 thousand over 13 weeks, equating to an average weekly burn of approximately $72,385.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eWeek\u003c\/th\u003e\n\u003cth\u003eStarting Cash Balance\u003c\/th\u003e\n\u003cth\u003eCash Inflow (Offering Net)\u003c\/th\u003e\n\u003cth\u003eWeekly Cash Outflow (Est. Burn)\u003c\/th\u003e\n\u003cth\u003eEnding Cash Balance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 1 (By Friday)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.93 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,900,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,757,615\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 2\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,757,615\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,685,230\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 3\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,685,230\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,612,845\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 4\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,612,845\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,540,460\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 5\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,540,460\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,468,075\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 6\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,468,075\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,395,690\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 7\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,395,690\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,323,305\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 8\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,323,305\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,250,920\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 9\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,250,920\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,178,535\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 10\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,178,535\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,106,150\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 11\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,106,150\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,033,765\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 12\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,033,765\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,961,380\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 13\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,961,380\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e-$72,385\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,888,995\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eAdditional Financial\/Statistical Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross Proceeds from June 2025 Offering: \u003cstrong\u003e$2.0 Million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eShares Sold in Offering: \u003cstrong\u003e610,399\u003c\/strong\u003e shares at \u003cstrong\u003e$3.36\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization (as referenced near offering): \u003cstrong\u003e$7 million\u003c\/strong\u003e or \u003cstrong\u003e$5.85M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Income for Fiscal Year ending 2024-12-31: \u003cstrong\u003e$-4.68M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss for Q3 2025 (quarter ending September 30, 2025): \u003cstrong\u003e$1.15 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and Equivalents as of September 30, 2025: \u003cstrong\u003e$1.93 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516265619605,"sku":"tcrt-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/tcrt-vrio-analysis.png?v=1740143447","url":"https:\/\/dcf-model.com\/fr\/products\/tcrt-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}